Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MT-7117

Phase 3Small molecule

TTanabe Pharma America, Inc.

1

Indications

12

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

EPPActive, not recruiting

EPPPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

EPP

NCT05005975

Clinical

Trials by Indication[1]

Interaction2 trials

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04793295·112 enrolled

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT03688022·50 enrolled

Tics2 trials

The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT06994286·40 enrolled

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT02834442·144 enrolled

Erythropoietic Protoporphyria2 trials

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Completed·TTanabe Pharma America, Inc.·Phase 2·NCT03520036·102 enrolled

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Completed·TTanabe Pharma America, Inc.·Phase 3·NCT04402489·184 enrolled

Renal Impairment1 trial

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04656795·32 enrolled

Hepatic Function1 trial

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04116476·23 enrolled

4 more indications

Systemic Sclerosis1 trial

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Completed·TTanabe Pharma America, Inc.·Phase 2·NCT04440592·76 enrolled

Oral1 trial

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT05241535·29 enrolled

EPP1 trial

A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Active, not recruiting·TTanabe Pharma America, Inc.·Phase 3·NCT05005975·286 enrolled

Unspecified1 trial

Mass Balance Study With MT-7117

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT03503266·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for MT-7117. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MT-7117 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MT-7117. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanabe Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTanabe Pharma America, Inc.

Related News